Current concepts in cannabinoid pharmacology

Indian Journal of Pharmacology

Volumn 33, Issue 3, 2001, Pages 170-184

  Kulkarni, S K ^a   Ninan, I ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Anandamide; Cannabinoid; Cannabis; Endocannabinoids; Receptors; Sativa

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID A RECEPTOR; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADENYLATE CYCLASE; ANANDAMIDE; BICUCULLINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABIS; DEXANABINOL; DRONABINOL; FLUPENTIXOL; GABAERGIC RECEPTOR AFFECTING AGENT; ION CHANNEL; LIGAND; METHANANDAMIDE; MUSCIMOL; NABILONE; NORBINALTORPHIMINE; OPIATE ANTAGONIST; RIMONABANT; STRYCHNINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIHYPERTENSIVE ACTIVITY; ANTINOCICEPTION; ASTROCYTE; BRAIN LEVEL; CANCER; CARDIOVASCULAR EFFECT; CHRONIC PAIN; DRUG ANTAGONISM; DRUG EFFECT; DRUG HYDROLYSIS; DRUG INACTIVATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; ENZYME INHIBITION; ENZYME REGULATION; GLAUCOMA; HUMAN; HYPERPOLARIZATION; IMMUNE SYSTEM; MOLECULAR CLONING; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NERVE CELL; NEUROMODULATION; NONHUMAN; OPEN FIELD BEHAVIOR; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPASTICITY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; VASODILATATION;

EID: 0034911360     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Early medical use of cannabis
2. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
3. A novel probe for the cannabinoid receptor
4. Molecular characterization of a peripheral receptor for cannabinoids
5. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes
6. Cannabinoid pharmacology
7. Determination and characterization of a cannabinoid receptor in rat brain
8. The discovery of non-classical cannabinoid analgesic
9. Nonclassical cannabinoid analgesics inhibit adenylate cyclase; Development of a cannabinoid receptor model
10. Molecular cloning of a human cannabinoid receptor which is also expressed in testis
11. Cloning and sequencing of a cDNA encoding the mouse brain type cannabinoid receptor protein
12. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
13. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
14. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study on the fetal, neonatal and adult human brain
15. 1 receptors in guinea pig small intestine
16. Evidence for the presence of cannabinoid receptors in mouse urinary bladder
17. 1 receptors in mouse vas-deferens
18. 1 receptors on peripheral sympathetic nerves
19. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
20. 1) in alveolar type-II cells in the lung-regulation by hydrocortisone
21. 2 peripheral cannabinoid receptor
22. 2) which is negatively coupled to adenylyl cyclase
23. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in ATT20 cells transfected with rat brain cannabinoid receptors
24. 2 receptors
25. The novel endogenous cannabinoid 2-arachidonyl glycerol is inactivated by neuronal and basophill like cells: Connections with anandamide
26. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP dependent process
27. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
28. New dawn on cannabinoid pharmacology
29. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor
30. Calcium-dependent release from rat brain of cannabinoid receptor binding activity
31. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization
32. New biological and clinical roles for the n-6 and n-3 fatty acids
33. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes
34. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide in brain and peripheral tissues of human and rat
35. Microsomal synthesis of fatty acid amides
36. Biosynthesis, release and degradation of the novel endogenous cannabinomimetic metabolite 2-arachidonylglycerol in mouse neuroblastoma cells
37. Potential biosynthetic connections between the two cannabinomimetic eicosanoids, anandamide and 2-arachidonylglycerol, in mouse neuroblastoma cells
38. N-arachidonylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues
39. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
40. Functional role of high-affinity anandamide transport, as revealed by selective-inhibition
41. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
42. A second endogenous cannabinoid ligand that modulates long term potentiation
43. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides
44. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma "anandamide amidohydrolase"
45. 2 receptors
46. Electrically-evoked acetylcholine-release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A
47. 1 cannabinoid receptor antagonist, SR 141716A
48. 1 cannabinoid receptors
49. Long-term synaptic transformation of hippocampal CA1 gammaaminobutyric acid synapses and the effect of anandamide
50. 2 dopamine receptors
51. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
52. The time course of the effects of different cannabinomimetics on prolactin and gonadotrophin secretion: Evidence in the effects of cannabinomimetics
53. Arachidonyl ethanolamide (anandamide) activates the paracellular part of hypothalamic paraventricular nucleus
54. Production and physiological actions of anandamide in the vasculature of the rat kidney
55. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
56. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
57. Cannabinoid agonists stimulate both receptor- and non-receptor- mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones
58. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase
59. Anandamide, an endogenous cannabinoid inhibits calcium currents as a partial agonist in N18neuroblastoma cells
60. Calcium independence of phosphatidylinositol hydrolysis-induced increase in cAMP accumulation in SKN-SH human neuroblastoma cells
61. Functional responses of cloned muscarinic receptors expressed in CHO-ki cells
62. Hormonal stimulation of adenylyl cyclase through Gi-protein β, γ subunits
63. Cloning and expression of a widely distributed (type-IV) adenylyl cyclase
64. Type specific regulation of adenylyl cyclase by G-protein β, γ subunits
65. Identification of a specified adenyl cyclase that may mediate odorant detection
66. Anandamide, an endogenous cannabinomimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction
67. i in the inhibition of adenylate cyclase by cannabinomimetic drugs
68. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells
69. i that amplifies ATP-mediated arachidonic acid release
70. 9 THC and anadamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats
71. 9 THC-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide
72. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids
73. 9-tetrahydrocannabinol to produce marked catalepsy in mice
74. R- Methanamide: A chiral novel anandamide possessing higher potency and metabolic stability
75. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N-, N-, diallyltyrosine-Aib-phenylalanine-leucine, ICL 174,864 or naloxone in mice
76. Potentiation of anandamide hypotension by the transport inhibitor, AM 404
77. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin
78. An endogenous cannabinoid as an endothelium-derived vasorelaxant
79. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentry
80. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation
81. Endocannabinoids: A new class of vasoactive substances
82. Anandamide, a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction
83. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat
84. Anandamide: An endogenous cannabinoid
85. Pharmaceutical sciences group/multiple sclerosis society. Therapeutic uses of cannabinoids